Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biom’Up Raises EUR 6.8 Million

Published: Friday, October 26, 2012
Last Updated: Friday, October 26, 2012
Bookmark and Share
These funds will be used to accelerate the company’s commercial development and finance clinical studies into two future innovative ranges of medical implants.

Biom’Up has announced that it has raised EUR 6.8 million in new funds from existing shareholders and acquired three new investors: the InnoBio fund, managed by CDC Entreprises under the ‘FSI France Investissement’ program, Viveris Management and OTC Asset Management.

As a result of the new funding, the new partners join the investors already associated with Biom’Up: Merieux Developpement, SHAM, Sofimac Partners, Aquasourca and L’Ameliane, alongside founders and managers Sylvain Picot (CEO) and Patricia Forest (deputy CEO and scientific director).

“Previous fundraising has enabled us to recruit the first members of the sales force and finance the R&D stages for two new product ranges,” explains Sylvain Picot, CEO of Biom’Up.

Picot continued, “The new funds will be used to strengthen the sales team significantly in order to accelerate the roll out of domestic and export sales.”

Biom’Up plans to recruit several additional sales representatives in the coming year for France. On the export side, the company will focus its sales efforts on the US and Europe.

At the same time, Biom’Up will finance a phase III clinical trial in Europe and the US for a new innovative range of products targeted at the major markets of surgery and regenerative medicine.

In addition, Biom’Up has implemented a development strategy in the US, filing initial applications (510k) with the Food and Drug Administration (FDA) and setting up a multi-disciplinary scientific advisory board consisting of recognized opinion leaders in France and the US.

“We are very pleased to support Biom’Up. We are impressed by the positioning and the quality of the products developed by the company,” says Thibaut Roulon, investment director at CDC Entreprises.

Roulon continued, “The products developed by Biom’Up offer a response to identified medical needs across major markets and meet the expectations of surgeons.”

Since 2009, Biom’Up has been selling its ranges of proprietary products: COVA™, a membrane for the prevention of adhesions and controlled healing, in Europe and the US and MATRI™ BONE, a bone regeneration matrix, in Europe. These ranges meet a strong demand in markets evaluated at several million euros.

COVA™ and MATRI™ BONE have proved to be clinically effective and add value for various types of surgery. These two initial ranges provide a new response to the requirements of surgery and regenerative medicine: for example, COVA™ makes corrective surgery more secure in cardiac paediatric cases.

Its handling and innovative mechanical properties also make it ideal for use in laparoscopy, delivering excellent results, especially in the prevention of adhesions in gastro-intestinal and gynecological surgery.

“The arrival of these new partners, which are highly committed to the life sciences sector, will enable us to cement our development in the European markets and penetrate the US market,” said Sylvain Picot. “This is also reflected in the strengthening of governance bodies within the company, enabling it to draw on experience and shareholder networks.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!